170 completed, 19 unknown, 10 terminated, 4 recruiting. 67 Phase 3, 60 Phase 4, 29 Phase 2, 28 Phase 1, 18 Not applicable.
Follow Salmeterol Xinafoate: new trials by email Literature Review of Salmeterol Xinafoate trials Research Report on Salmeterol Xinafoate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Muscle Anabolic Response to β2-adrenergic Stimulation With Increased Amino Acid Availability. Salmeterol + amino acid availability, Salmeterol + placebo, Placebo + placebo - Healthy | Not applicable | Recruiting | University of Copenhagen | 36 | 2024-10-31 | 2025-04-09 |
| Salmeterol Effect on Exercise Performance Salmeterol, Placebo - Healthy | Not applicable | Recruiting | University of Copenhagen | 36 | 2024-10-31 | 2025-04-09 |
| ANTES B+ Clinical Trial Trelegy Ellipta 100/62.5/25Mcg Inh 30D, Brimica, Duaklir - Chronic Obstructive Pulmonary Disease | Phase 4 | Terminated | Fundacio Privada Mon Clinic Barcelona | 48 | 2024-02-29 | 2025-08-14 |
| Advair HFA in Healthy and HAPE Predisposed Subjects Advair HFA, Placebo - Altitude Edema | Phase 1 / Phase 2 | Recruiting | University of Colorado, Denver | 60 | 2023-12-12 | 2025-09-22 |
| Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, ADVAIR DISKUS® 500/50 - Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 34 | 2023-08-22 | 2023-09-06 |
| Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, ADVAIR DISKUS® 250/50 - Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 34 | 2023-08-01 | 2023-08-31 |
| Bioequivalence Study for Fluticasone Propionate 100 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers Fluticasone propionate 1000 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, ADVAIR DISKUS 100/50 - Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 34 | 2023-02-17 | 2023-03-09 |
| Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals, ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK, Placebo - Asthma | Phase 3 | Unknown | Respirent Pharmaceuticals Co Ltd. | 451 | 2023-01-30 | 2023-03-01 |
| Bioequivalence Study of Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers Test, Reference - Bioequivalence, Asthma | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 18 | 2021-10-01 | 2021-10-20 |
| Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in Asthma Salmeterol Xinafoate, Salmeterol Fluticasone - Asthma | Phase 4 | Unknown | Imperial College London | 24 | 2021-07-23 | 2023-04-25 |
| A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers Test, Reference - Bioequivalence, Asthma | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 50 | 2021-01-18 | 2021-04-20 |
| Replication of the POET-COPD Trial in Healthcare Claims Data Salmeterol, Tiotropium - Chronic Obstructive Pulmonary Disease | Completed | Brigham and Women's Hospital | 8716 | 2020-09-22 | 2023-07-27 | |
| A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent, ADVAIR DISKUS® 500/50 - Bioequivalence | Phase 1 | Completed | Respirent Pharmaceuticals Co Ltd. | 34 | 2020-09-22 | 2021-01-20 |
| A Pilot Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent, ADVAIR DISKUS® 500/50 - Bioequivalence | Phase 1 | Completed | Respirent Pharmaceuticals Co Ltd. | 14 | 2020-09-01 | 2021-03-09 |
| A Pilot Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent, ADVAIR DISKUS® 250/50 - Bioequivalence | Phase 1 | Completed | Respirent Pharmaceuticals Co Ltd. | 14 | 2020-08-24 | 2021-01-20 |
| A Pivotal Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers Test Product, Reference Product - Bioequivalence | Phase 1 | Completed | Respirent Pharmaceuticals Co Ltd. | 34 | 2020-07-01 | 2021-03-09 |
| Yiqi Huoxue Huatan Granule for Reducing Mortality in COPD With Chronic Respiratory Failure Yiqi Huoxue Huatan granule, Placebo Yiqi Huoxue Huatan granule - Chronic Obstructive Pulmonary Disease, Chronic Respiratory Failure | Phase 3 | Unknown | Peking University People's Hospital | 372 | 2019-10-08 | 2020-01-07 |
| A Bioequivalence Study Between Fluticasone and Salmeterol vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade Test Product (Fluticasone propionate and salmeterol xinafoate inhalation powder/Respirent Pharmaceuticals), Reference Product (SERETIDE DISKUS® 100/50 inhalation powder/GSK), Activated Charcoal suspension - Bioequivalence | Phase 1 | Completed | Respirent Pharmaceuticals Co Ltd. | 36 | 2019-10-01 | 2020-07-07 |
| Pooled Analysis FP_SX_250_50 Test, Reference - Asthma | Completed | Respirent Pharmaceuticals Co Ltd. | 82 | 2019-06-02 | 2021-03-10 | |
| A Bioequivalence Study Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 Inhalation Powder/GSK in Healthy Volunteers Test Product, Reference Product - Bioequivalence | Phase 1 | Completed | Respirent Pharmaceuticals Co Ltd. | 34 | 2019-05-21 | 2019-09-10 |
Showing 20 of 208. Sign in to see all of them.
Pulmonary Disease, Chronic Obstructive (99) · Asthma (76) · Inflammation (5) · Bronchitis, Chronic (4) · Dyspnea (4) · Emphysema (4) · Asthma, Exercise-Induced (3) · Bronchial Hyperreactivity (2) · Hypersensitivity (2) · Lung Diseases (2) · Obesity (2) · Respiratory Aspiration (2) · Rhinitis, Allergic (2) · Altitude Sickness (1) · Anxiety Disorders (1)
GlaxoSmithKline (42) · Boehringer Ingelheim (23) · Respirent Pharmaceuticals Co Ltd. (17) · Novartis Pharmaceuticals (15) · AstraZeneca (7) · Novartis (6) · Neothetics, Inc (5) · Brigham and Women's Hospital (4) · Organon and Co (4) · Teva Branded Pharmaceutical Products R&D, Inc. (4) · University of Dundee (4) · Chiesi Farmaceutici S.p.A. (3) · Henan University of Traditional Chinese Medicine (3) · Sumitomo Pharma America, Inc. (3) · University of Copenhagen (3)
United States (72) · Germany (47) · United Kingdom (26) · Spain (25) · Greece (24) · Italy (21) · Netherlands (21) · Belgium (18) · Canada (18) · Russia (18) · South Africa (17) · Denmark (16) · Hungary (16) · Czechia (15) · France (15)
Ioannis Stefanidis, Professor (9) · Chrysoula Doxani, MD, MSc, PhD (4) · Elliot Israel, MD (3) · Maria Feldman (3) · Arthur F Gelb, MD (2) · Catherine Bonuccelli (2)
PMID 36472162, PMID 27216137, PMID 20075384, PMID 23613569, PMID 24998880, PMID 10903223, PMID 15500895, PMID 15806036, PMID 15922813, PMID 16322642, PMID 16772309, PMID 17507702, PMID 17610727, PMID 17905575, PMID 18039368, PMID 18951618, PMID 19237390, PMID 19436693, PMID 19820080, PMID 19841453, PMID 19878590, PMID 19897551, PMID 19910613, PMID 19932356, PMID 20167147, PMID 20170333, PMID 20298399, PMID 20568384, PMID 20622031, PMID 20705799, PMID 20813884, PMID 20850959, PMID 20851928, PMID 20874458, PMID 20979471, PMID 21227674, PMID 21367594, PMID 21397482, PMID 21428765, PMID 21627828, PMID 21737561, PMID 21799027, PMID 21807250, PMID 21980058, PMID 22152089, PMID 22158330, PMID 22192967, PMID 22235841, PMID 22560478, PMID 22749044
2016 (3), 2008 (2), 2014 (2), U10HL074073 (2), U10HL074204 (2), U10HL074208 (2), U10HL074212 (2), U10HL074218 (2), U10HL074225 (2), U10HL074227 (2), U10HL074231 (2), 2015 (1), 2017 (1), 2019 (1), 2023 (1)